Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Change in Accured Expenses: 2020-2025

Historic Change in Accured Expenses for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $24.3 million.

  • Mirum Pharmaceuticals' Change in Accured Expenses rose 90.92% to $24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.0 million, marking a year-over-year increase of 28.73%. This contributed to the annual value of $40.3 million for FY2024, which is 30.98% up from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Change in Accured Expenses is $24.3 million, which was up 130.18% from $10.6 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Change in Accured Expenses high stood at $24.3 million for Q3 2025, and its period low was -$8.1 million during Q1 2022.
  • Over the past 3 years, Mirum Pharmaceuticals' median Change in Accured Expenses value was $10.6 million (recorded in 2025), while the average stood at $10.7 million.
  • Per our database at Business Quant, Mirum Pharmaceuticals' Change in Accured Expenses slumped by 344.92% in 2021 and then spiked by 250,660.00% in 2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Change in Accured Expenses (Quarterly) stood at $9.0 million in 2021, then tumbled by 100.06% to -$5,000 in 2022, then surged by 250,660.00% to $12.5 million in 2023, then fell by 25.45% to $9.3 million in 2024, then skyrocketed by 90.92% to $24.3 million in 2025.
  • Its Change in Accured Expenses stands at $24.3 million for Q3 2025, versus $10.6 million for Q2 2025 and $11.7 million for Q1 2025.